Figure EV3. The presence of serum during biosynthesis does not influence SARS‐CoV‐2 infectious entry pathways.

• A, B
  A549* cells expressing or lacking TMPRSS2 were pretreated with camostat mesylate at 500 µM (A) or SB412515 at 10 µM (B) and subsequently infected with SARS‐CoV‐2 (MOI of 0.2) produced in the presence or absence of serum. Infection was performed in the continuous presence of the drugs. Infected cells were quantified by flow cytometry as described in Fig 1D, and data were normalized to samples where inhibitors had been omitted. n = 4.

Data information: Data are expressed as mean ± SEM from two independent experiments.

Source data are available online for this figure.